As one of the first facilities to register under section 503B, Pine Pharmaceuticals is celebrating ten years of uncompromising excellence!
Founded in 2014 by father and son Alfonse Muto and Alfonse J. Muto, Pharm.D., Pine Pharmaceuticals established itself as an FDA-registered 503B outsourcing facility. Since then, Pine has been relentlessly committed to supplying affordable, high-quality, ready-to-administer compounds and repackaged products. This dedication pushed the company to the forefront of the ophthalmology industry and later enabled it to expand its portfolio to service specialty practices, ambulatory surgery centers, and hospitals all across the country.
The journey to Pine’s current status has been characterized by continuous growth. Through strategic initiatives, Pine Pharmaceuticals’ gradual expansion has not only enabled the evolution of its product offerings but also its manufacturing capabilities. Starting in a 5,000-square-foot facility, Pine’s move to Riverwalk Parkway in 2018 was the catalyst for advancement. With a 50,000-square-foot expansion in 2021, Pine tripled its size, bringing the company’s overall square footage to a remarkable 75,000 square feet by 2022, ultimately increasing its automation and in-house testing abilities.
“Our achievements are a testament to the support and dedication of our outstanding team here at Pine and all our valued partners. Their contributions have been essential to our journey for the past decade, and we can’t thank them enough.”
– Alfonse J. Muto, Pharm.D.
Today, Pine produces over 50 life-saving drug products from its state-of-the-art facility, distributing millions of units annually nationwide.